For Immediate Release
Chicago, IL – February 12, 2013 – Zacks Equity Research highlights Tyson Foods (TSN) as the Bull of the Day and Goldcorp (GG) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Novo Nordisk (NVO), Sanofi (SNY) and Bayer AG (BAYRY).
Full analysis of all these stocks is available at http://at.zacks.com/?id=2678.
Here is a synopsis of all five stocks:
With the economy seemingly back on track, many investors have looked to higher beta stocks. However, there are also plenty of firms in corners like the consumer staples market which could still be great bets during this environment.
One such company is Tyson Foods (TSN), the world’s largest fully-integrated producer, processor, and marketer of chicken and poultry-based food products. This firm may have been overlooked in the recent market surge, but recent trends suggest that it could still have plenty of room to run, while still being a lower risk stock.
TSN has seen a big move higher in terms of analyst expectations over the past few weeks. With nine estimates on the company, six have moved higher in the past week for both the current quarter, and the current fiscal year periods.
If that wasn’t enough, the magnitude of these revisions has also been enormous. Current quarter estimates have jumped from 30 cents a share to 46 cents a share in the past 90 days, while full year estimates have leaped from $1.59 a share to $2.02 for the same time period.
While gold has broadly outperformed stocks over the past few years, this has pretty much reversed in the past few months. Now, safety oriented precious metals are slumping while stocks are marching towards fresh all-time highs.
This trend has led many to abandon gold for the time being as its traditional role as a store of value and inflation hedge isn’t in demand in these types of markets. Gold’s lack of appeal could continue now that China and other emerging markets are back on track, while Europe’s debt issues have subsided for the time being.
While this has had a negative impact on gold prices, it has been even worse news for gold miners. That is because these often trade as a leveraged play on precious metal prices, so they can often underperform spot prices when metals are slumping.
In particular, this situation has been especially bad news for Goldcorp (GG), a firm that could continue to see weakness if current conditions hold.
Latest Posts on the Zacks Analyst Blog:
Novo Nordisk Suffers Setback
Novo Nordisk (NVO) recently faced a setback when the US Food and Drug Administration (:FDA) declined to approve its diabetes candidates, Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart), on the basis of the submitted data.
The FDA issued a complete response letter (CRL) asking Novo Nordisk to conduct a dedicated cardiovascular outcomes study and provide additional cardiovascular data.
Moreover, the FDA said that it will not grant approval to these candidates until the company resolves the issues mentioned in a warning letter given by the FDA in Dec 2012. The warning letter specified violations of current good manufacturing practice (:CGMP) regulations for finished pharmaceuticals at the company’s Novo Alle, Bagsvaerd Denmark facility.
Meanwhile, we note that both Tresiba and Ryzodeg are approved in Japan , the EU and Mexico . In the EU, Novo Nordisk is planning to launch Tresiba first and Ryzodeg a year later. Tresiba and Ryzodeg will be available in Novo Nordisk’s latest prefilled insulin pen named FlexTouch in Europe . Tresiba will initially be launched in the UK and Denmark in the first half of 2013 and in other European markets throughout 2013 and 2014.
We are discouraged by the CRL issued by the FDA. Considering Novo Nordisk’s statement that it will not be in a position to provide the required data in 2013, we expect a significant delay in the US approval of Tresiba and Ryzodeg. The US approval of Tresiba and Ryzodeg would have strengthened Novo Nordisk’s diabetes franchise. We expect shares to react negatively to the news.
Novo Nordisk currently carries a Zacks Rank #1 (Strong Buy). Other large-cap pharma companies Sanofi (SNY) and Bayer AG (BAYRY) both have Zacks Rank #2 (Buy) ratings.
Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: https://twitter.com/zacksresearch
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339
More From Zacks.com